Patients with schizophrenia are vulnerable to pneumonia. Clozapine is associated with the greatest risk of pneumonia. We investigated the risk factors of pneumonia in patients with schizophrenia who use clozapine.
We used a large cohort of patients with schizophrenia (N = 22,774) who newly use clozapine (baseline). We divided the data set into a training cohort (entry between 1998 and 2008, n = 18,496) and test cohort (entry between 2009 and 2012, n = 4278), where 483 and 168 patients developed pneumonia requiring hospitalization within 1 year after baseline, respectively. For prediction, we developed a static model using Cox proportional hazards regression and a dynamic model using Cox regression with time-dependent modeling. Areas under receiver operating curves (AUCs) for the predictive model were estimated in the training cohort and then in the test cohort for validation.
Based on the baseline characteristics, the static model for predicting pneumonia in 3 periods (90, 180, and 365 days) was unsatisfactory (AUCs, 0.64, 0.64, and 0.65, respectively). The predictors were older age, male sex, history of nonpsychiatric hospitalization, dementia, asthma, and tuberculosis within 1 year before baseline. However, the results were improved (AUCs, 0.83, 0.79, and 0.77, respectively) after control for time-dependent variables, namely, duration of clozapine use and concomitant medications (ie, benzodiazepines, valproic acid, systemic corticosteroids).
Several risk factors for predicting subsequent pneumonia after initial use of clozapine were explored, including older age, male, history of nonpsychiatric hospitalization, dementia, asthma, tuberculosis, benzodiazepines, valproic acid, systemic corticosteroids, and the use duration of clozapine. Clinical staff can use the risk factors to administer evidence-based treatment.
From the *Department of Psychiatry, National Taiwan University Hospital;
†Department of Psychiatry, Tri-Service General Hospital; School of Medicine, National Defense Medical Center;
‡Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University;
§Psychiatric Research Center, Taipei Medical University Hospital;
∥Department of Psychiatry, Mackay Memorial Hospital and Department of Psychiatry, Mackay Medical College; and
¶Taipei City Psychiatric Centre, Taipei City Hospital, Taipei, Taiwan.
Received June 30, 2018; accepted after revision March 20, 2019.
Reprints: Chian-Jue Kuo, MD, PhD, Department of General Psychiatry, Taipei City Psychiatric Center, 309 Sung-Te Rd, Taipei, 110, Taiwan (e-mail: firstname.lastname@example.org).
This research was supported by grants from the Ministry of Science and Technology, Taiwan (MOST 105-2314-B-532-006-MY3 and NSC 102-2628-B-532-001-MY3), and Taipei City Hospital (10501-62-015). The funding sources had no involvement in the study design, data collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.psychopharmacology.com).
Online date: June 11, 2019